Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg , will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK.
- Read more about Glenmark Ryaltris nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/glenmark-ryaltris-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age
No comments:
Post a Comment